menu
    • menu
    [{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Sialidase L

    Menu

    Sialidase L

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ansun Biopharm

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Ansun Biopharm

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sialidase L

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ansun Biopharma Enrolls First Patient in Proof of Concept Trial of DAS181 for the Treatment of COVID-19

                            Details : New study will build on recent clinical evidence showing efficacy of DAS181 in improving symptoms of patients with severe COVID-19.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            April 15, 2020

                            Lead Product(s) : Sialidase L

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ansun Biopharm

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Ansun Biopharm

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sialidase L

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment

                            Details : In the first 14 days of study, the first two patients no longer required supplemental oxygen, and showed stabilized vital signs, increased oxygen saturation, and resolution of infiltrates.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            April 02, 2020

                            Lead Product(s) : Sialidase L

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth